Yale guide to fighting drug patent barriers
How human rights can be used to challenge oppressive intellectual property laws
Evergreen Novartis
The Swiss pharma giant’s challenge to India’s patent law, now in the Supreme Court, may help define drug efficacy
Annihilation of caste and copyright claims
Ambedkar’s works have been published widely and yet pose a copyright conundrum
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
Monsanto does it again
The biotech seed giant sues a farmer for planting unbranded commodity seeds bought in the open market for patent infringement
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
It’s still open season for bio-piracy
Rich nations block accord on benefit-sharing rules for the world’s genetic resources
Righting the copywrong
Amending the Copyright Act to give directors, composers and musicians rights over their work has corrected a historic wrong but trouble is brewing
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
Any cheers for Doha pact?
The Doha Declaration on protecting public health is a decade old, but developing countries have not been able to make use of TRIPs flexibilities
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
No climate for cleantech
Most of the clean energy innovations are with just six rich countries and hardly any technology is coming to developing nations
Mark Lynas and the demeaning of science
He’s fuzzy on facts and low on science, but the campaigner gets big media support
A pre-emptive strike against Monsanto
American organic farmers are trying to ensure the biotech giant cannot sue them
Pursuing a nationalist IPR policy
India has enough laws to protect its intellectual property rights. It is the implementation that is wanting
Bringing Google to book
Google’s digital library project went too far, creating a monopoly over the heritage of books
Patent issues delaying Ebola cure
Canada's exclusive licensing rights of its Ebola patent to a US firm are holding up global development of a vaccine
What Durban did not discuss
IPRs are blocking access to mitigation and adaptation technologies. India offers a way out
Disclosure-shy industry
Pharma and biotech firms are lobbying hard to block disclosure of origin of genetic material used in inventions, but they also raise thorny issues
New endosulfan ploy
Industry is sidestepping issues by pitching the proposed UN ban on endosulfan as the battle between generics and patented pesticides
Predatory EU pacts
EU is pushing India and Canada to sign free trade agreements that will hurt their generic drugs—and the outrage is global
WTO gives India a clean chit
Apex trade regulator finds nothing amiss in India's intellectual property laws after exhaustive review
Unholy smoke!
Inclusion of intellectual property in bilateral investment agreements is injurious to the health of developing nations
Testing the CL route
Roche’s Herceptin will be a test case for government and generics industry as India readies to issue compulsory licences for life-saving drugs
Big tobacco blows new smoke rings
A third front has opened up in their war on Australia’s cigarette packaging rules